"Tosyl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Toluenesulfonyl compounds with general formula CH3C6H4S(O2)R” widely used to block amino groups in the course of syntheses of drugs and other biologically active compounds.
Descriptor ID |
D014105
|
MeSH Number(s) |
D02.455.426.559.389.832.661 D02.886.590.887
|
Concept/Terms |
Tosyl Compounds- Tosyl Compounds
- Compounds, Tosyl
- Toluenesulfonyl Compounds
- Compounds, Toluenesulfonyl
|
Below are MeSH descriptors whose meaning is more general than "Tosyl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Tosyl Compounds".
This graph shows the total number of publications written about "Tosyl Compounds" by people in this website by year, and whether "Tosyl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1999 | 1 | 0 | 1 |
2000 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
2004 | 0 | 2 | 2 |
2005 | 0 | 3 | 3 |
2006 | 0 | 2 | 2 |
2007 | 1 | 1 | 2 |
2008 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2010 | 0 | 2 | 2 |
2011 | 1 | 0 | 1 |
2013 | 1 | 3 | 4 |
2016 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tosyl Compounds" by people in Profiles.
-
Leukotrienes, a potential target for Covid-19. Prostaglandins Leukot Essent Fatty Acids. 2020 10; 161:102174.
-
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 05 20; 36(15):1498-1504.
-
Photoacoustic calorimetry studies of CO photo-dissociation from chloramine-T modified horse heart cytochrome-c. Arch Biochem Biophys. 2016 Dec 15; 612:17-21.
-
Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
-
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8.
-
Enantioselective and rapid Rh-catalyzed arylation of N-tosyl- and N-nosylaldimines in methanol. J Org Chem. 2014 Sep 05; 79(17):8077-85.
-
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71.
-
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 04; 368(14):1314-25.
-
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):540-5.
-
Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):529-33.